Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal experimental research without human data.
PubMed 20660763 · doi:10.1073/pnas.0914730107
What was done
Researchers investigated whether resolvin E1 (RvE1) acts directly on intestinal epithelial cells to promote mucosal resolution. They evaluated ChemR23 receptor expression, performed microarray profiling on RvE1-exposed epithelial cells, measured intestinal alkaline phosphatase (ALPI) expression and enzyme activity, and tested LPS detoxification via attenuation of NF-kappaB signaling. They also assessed ALPI-mediated growth inhibition of Escherichia coli and evaluated RvE1 administration with or without ALPI inhibition in a murine dextran sulfate sodium (DSS) colitis model.
What was found
The abstract reports no exact numbers, percentages, or effect sizes. Qualitatively, ChemR23 was expressed on intestinal epithelial cells, and RvE1 exposure induced ALPI expression and significantly enhanced ALPI enzyme activity. RvE1-exposed epithelia detoxified LPS, and ALPI retarded E. coli growth. In murine DSS colitis, RvE1 significantly improved disease activity indices (body weight and colon length) concomitant with increased epithelial ALPI expression. Pharmacological inhibition of ALPI worsened colitis severity and partially abrogated the protective effects of RvE1.
Why it matters
This work identifies epithelial induction of intestinal alkaline phosphatase and subsequent LPS detoxification as a pathway by which resolvin E1 resolves mucosal inflammation in the gut.
Limits
The study is entirely preclinical, relying on cell culture models and an acute chemically induced mouse model of colitis. The abstract does not report sample sizes, specific quantitative measurements, or variance. Findings cannot be directly extrapolated to human inflammatory bowel disease without clinical testing.
Cited by
- supports In animal studies, omega-3 fatty acids in the gut increase levels of intestinal alkaline phosphatase (IAP), which degrades LPS and kills LPS-producing bacteria.